Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ciliary neurotrophic factor

Generic Name: Ciliary neurotrophic factor

Drug Type: Biotech

CAS Number: 133423-39-9

Unique Ingredient Identifier: CR102F038W

Overview

NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.

Background

Indication

Investigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).

Associated Conditions

No associated conditions information available.

Clinical Trials

Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma

Phase 2

Recruiting

Posted: 2020/10/06

Sponsor:Stanford University

ID:NCT04577300

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

Phase 2

Active, not recruiting

Posted: 2016/08/11

Sponsor:Stanford University

ID:NCT02862938

Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

Phase 2

Completed

Posted: 2012/02/10

Sponsor:

Neurotech Pharmaceut...

ID:NCT01530659

NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement

Phase 1

Completed

Posted: 2011/08/08

Sponsor:

Jeffrey L Goldberg

ID:NCT01411657

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

Phase 1

Completed

Posted: 2011/08/03

Sponsor:

Jeffrey L Goldberg

ID:NCT01408472

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment

a month ago

DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials.

Phase 3 Trial Shows Promising Results for Novel Encapsulated Cell Therapy in MacTel Treatment

3 months ago

Phase 3 clinical trials of NT-501, an encapsulated cell therapy delivering CNTF, demonstrated significant reduction in disease progression for macular telangiectasia type 2 patients, with up to 52% reduction in ellipsoid zone loss.

Long-term Study Shows Sustained Benefits of NT-501 Cell Therapy for Macular Telangiectasia Type 2

4 months ago

Nine-year follow-up data demonstrates continued safety and efficacy of NT-501 (revakinagene taroretcel) in treating macular telangiectasia type 2. The encapsulated cell therapy, developed by Neurotech Pharmaceuticals, shows promising results in reducing ellipsoid zone loss while maintaining a favorable safety profile.

Five Advanced Therapeutics Poised for FDA Decisions in 2025

4 months ago

The FDA is set to make pivotal decisions on five advanced therapeutics in 2025, targeting a range of conditions from hemophilia to macular telangiectasia. These therapies, including Fitusiran and Vutrisiran, have shown promising results in clinical trials, offering new hope for patients with rare and complex diseases.

Macular Telangiectasia Cell Therapy NT-501 Achieves Primary Endpoints in Phase 3 Trials

5 months ago

NT-501, an encapsulated cell therapy, has demonstrated success in treating macular telangiectasia type 2 by meeting its primary endpoints in two phase 3 clinical trials.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy